Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01408160 |
|
Recruitment Status
: Unknown
Verified January 2016 by Amit Verma, Albert Einstein College of Medicine of Yeshiva University.
Recruitment status was: Recruiting
First Posted
: August 3, 2011
Last Update Posted
: January 15, 2016
|
Sponsor:
Albert Einstein College of Medicine, Inc.
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Amit Verma, Albert Einstein College of Medicine of Yeshiva University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | June 2016 |
| Study Completion Date : | No date given |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):